for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adaptimmune Therapeutics PLC - ADR

ADAP.OQ

Latest Trade

0.73USD

Change

-0.08(-9.38%)

Volume

125,272

Today's Range

0.71

 - 

0.85

52 Week Range

0.71

 - 

6.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Adaptimmune Qtrly Loss Per Share $0.06

Nov 6 (Reuters) - Adaptimmune Therapeutics PLC <ADAP.O>::ADAPTIMMUNE REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE.QTRLY REVENUE $0.2 MILLION VERSUS $40.8 MILLION.SEES EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL FUND CURRENT OPERATIONS THROUGH Q3 OF 2020.QTRLY LOSS PER SHARE $0.06.ADAPTIMMUNE -FACTORS RAISE SUBSTANTIAL DOUBT ABOUT ABILITY TO CONTINUE AS A GOING CONCERN FOR AT LEAST 1 YEAR FROM ISSUANCE OF SEPT 30 QTRLY STATEMENTS.IN IMMEDIATE FUTURE, COMPANY PLANS TO CONTINUE TO PRIORITIZE AND REVIEW ONGOING CLINICAL DEVELOPMENT PROJECTS AND COSTS.AIMS TO FOCUS OPERATIONS ON ADP-A2M4 SPEARHEAD-1, ADP-A2M4CD8 SURPASS, AND ADP-A2AFP TRIALS IN IMMEDIATE FUTURE.Q3 EARNINGS PER SHARE VIEW $-0.31, REVENUE VIEW $1.5 MILLION -- REFINITIV IBES DATA.

Adaptimmune Therapeutics PLC Files For Mixed Shelf Of Up To $400 Million

Aug 30 (Reuters) - Adaptimmune Therapeutics PLC <ADAP.O>::ADAPTIMMUNE THERAPEUTICS PLC FILES FOR MIXED SHELF OF UP TO $400 MILLION – SEC FILING.

Adaptimmune And Noile-Immune Announce Pact To Develop Spear T-Cell Products For Cancer

Aug 27 (Reuters) - Adaptimmune Therapeutics PLC <ADAP.O>::ADAPTIMMUNE AND NOILE-IMMUNE ANNOUNCE AGREEMENT TO DEVELOP SPEAR T-CELL PRODUCTS EXPRESSING IL-7 AND CCL19 AS A NEXT-GENERATION TREATMENT FOR CANCER PATIENTS.ADAPTIMMUNE THERAPEUTICS PLC - WILL CO-DEVELOP NEXT-GENERATION SPEAR T-CELL PRODUCTS, INCORPORATING NOILE-IMMUNE'S PRIME TECHNOLOGY.ADAPTIMMUNE THERAPEUTICS PLC - NOILE-IMMUNE AND ADAPTIMMUNE WILL COLLABORATE ON PRECLINICAL DEVELOPMENT OF NEXT-GENERATION SPEAR T-CELLS.ADAPTIMMUNE THERAPEUTICS PLC - ADAPTIMMUNE WILL HAVE EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE RESULTING PRODUCTS ON A WORLDWIDE BASIS.ADAPTIMMUNE THERAPEUTICS PLC - ADAPTIMMUNE WILL MAKE AN UPFRONT CASH PAYMENT AND MILESTONE PAYMENTS TO NOILE‑IMMUNE OF UP TO $312M ACROSS ALL PROGRAMS.ADAPTIMMUNE THERAPEUTICS PLC - NOILE-IMMUNE IS ALSO ENTITLED TO RECEIVE MID-SINGLE DIGIT ROYALTIES ON NET SALES OF RESULTING PRODUCTS.ADAPTIMMUNE THERAPEUTICS PLC - COMPANIES PLAN TO GAIN REGULATORY APPROVAL FOR HUMAN TESTING OF FIRST TARGET PROGRAM BY 2021..

New Executive Team Announced At Adaptimmune

Aug 1 (Reuters) - Adaptimmune Therapeutics PLC <ADAP.O>::NEW EXECUTIVE TEAM ANNOUNCED AT ADAPTIMMUNE.ADAPTIMMUNE THERAPEUTICS PLC - ADRIAN RAWCLIFFE TO ASSUME CEO ROLE FROM SEPTEMBER 1, 2019.ADAPTIMMUNE THERAPEUTICS PLC - RAFAEL AMADO, PRESIDENT RESEARCH AND DEVELOPMENT, WILL LEAVE COMPANY ON AUGUST 12, 2019.ADAPTIMMUNE THERAPEUTICS PLC - COMPANY IS RECRUITING A CHIEF MEDICAL OFFICER AND A CHIEF FINANCIAL OFFICER.

Adaptimmune Reports Second Quarter 2019 Financial Results And Business Update

Aug 1 (Reuters) - Adaptimmune Therapeutics PLC <ADAP.O>::ADAPTIMMUNE REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE.ADAPTIMMUNE THERAPEUTICS PLC - QTRLY REVENUE WAS $0.2 MILLION VERSUS $9.0 MILLION.ADAPTIMMUNE THERAPEUTICS PLC - QTRLY LOSS PER SHARE $0.07.ADAPTIMMUNE THERAPEUTICS - EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL FUND COMPANY'S CURRENT OPERATIONS THROUGH Q3 OF 2020.

Adaptimmune Starts Trial with ADP-A2M4 SPEAR T‑cells For Patients With Synovial Sarcoma

July 25 (Reuters) - Adaptimmune Therapeutics PLC <ADAP.O>::ADAPTIMMUNE STARTS SPEARHEAD-1 TRIAL WITH ADP-A2M4 SPEAR T-CELLS FOR PATIENTS WITH SYNOVIAL SARCOMA OR MRCLS.ADAPTIMMUNE THERAPEUTICS PLC - COMPELLING DATA REPORTED WITH ADP-A2M4 SPEAR T-CELLS IN SYNOVIAL SARCOMA -.ADAPTIMMUNE THERAPEUTICS PLC - ADAPTIMMUNE PLANS TO LAUNCH A TCR T-CELL THERAPY IN 2022 -.

Adrian Rawcliffe To Succeed James Noble As Adaptimmune Chief Executive Officer

June 27 (Reuters) - Adaptimmune Therapeutics PLC <ADAP.O>::ADRIAN RAWCLIFFE TO SUCCEED JAMES NOBLE AS ADAPTIMMUNE CHIEF EXECUTIVE OFFICER.ADAPTIMMUNE THERAPEUTICS - TRANSITION TO OCCUR WHEN JAMES RETIRES FROM EXECUTIVE DUTIES, TRANSITIONS TO NON-EXECUTIVE DIRECTOR ROLE ON BOARD ON SEPT 1.ADAPTIMMUNE THERAPEUTICS PLC - COMPANY HAS STARTED A GLOBAL SEARCH FOR A NEW CFO, WHICH WILL BE SUBJECT OF A SEPARATE ANNOUNCEMENT..ADAPTIMMUNE THERAPEUTICS - ADRIAN RAWCLIFFE, CURRENTLY CHIEF FINANCIAL OFFICER OF COMPANY, WILL SUCCEED JAMES NOBLE AS CHIEF EXECUTIVE OFFICER.

Adaptimmune Reports Q1 Loss Per Share $0.04

May 6 (Reuters) - Adaptimmune Therapeutics PLC <ADAP.O>::ADAPTIMMUNE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.04.Q1 EARNINGS PER SHARE ESTIMATE $-0.31 -- REFINITIV IBES DATA.FINANCIAL GUIDANCE UPDATED.ADAPTIMMUNE THERAPEUTICS - BELIEVES EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL FUND COMPANY'S CURRENT OPERATIONS INTO Q3 OF 2020.ADAPTIMMUNE THERAPEUTICS - REVENUE FOR THREE-MONTH PERIOD ENDED MARCH 31, 2019 WAS NIL, COMPARED TO $8.2 MILLION FOR SAME PERIOD IN 2018.AS OF MARCH 31, CO HAD CASH AND CASH EQUIVALENTS OF $49.9 MILLION AND TOTAL LIQUIDITY OF $168.2 MILLION.

Adaptimmune Therapeutics - Significant Clinical Progress As Adaptimmune Announces Responses With ADP-A2m4 In Synovial Sarcoma And Antitumor Activity In Other Solid Tumors

May 6 (Reuters) - Adaptimmune Therapeutics PLC <ADAP.O>::SIGNIFICANT CLINICAL PROGRESS AS ADAPTIMMUNE ANNOUNCES RESPONSES WITH ADP-A2M4 IN SYNOVIAL SARCOMA AND ANTITUMOR ACTIVITY IN OTHER SOLID TUMORS.ADAPTIMMUNE - ANNOUNCED CLINICAL PROGRESS WITH PARTIAL RESPONSES IN 4/5 SYNOVIAL SARCOMA PATIENTS TREATED WITH ABOUT 10 BILLION CELLS IN ADP-A2M4 PILOT STUDY.ADAPTIMMUNE THERAPEUTICS - WILL INITIATE SPEARHEAD-1 TRIAL IN PATIENTS WITH SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA (MRCLS) LATER THIS YEAR.

Orbimed Advisors Reports 4.69 Pct Stake In Adaptimmune Therapeutics As Of Sept 7

Oct 10 (Reuters) - Orbimed Advisors LLC: :ORBIMED ADVISORS LLC SAYS CAUSED OPI V TO BUY SHARES OF ADAPTIMMUNE THERAPEUTICS FOR PURPOSE OF INVESTMENT IN CO - SEC FILING.ORBIMED ADVISORS LLC SAYS CAUSED OPI V TO BUY SHARES OF ADAPTIMMUNE NOT WITH INTENTION OF ACQUIRING CONTROL OF ADAPTIMMUNE ON BEHALF OF OPI V.ORBIMED ADVISORS LLC REPORTS 4.69 PERCENT STAKE IN ADAPTIMMUNE THERAPEUTICS PLC AS OF SEPT 7.ORBIMED ADVISORS LLC PREVIOUSLY REPORTED 5.44 PERCENT STAKE IN ADAPTIMMUNE THERAPEUTICS PLC AS OF MARCH 27.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up